TLCV2-RB1 Citations (2)

Originally described in: Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer.
Barger CJ, Branick C, Chee L, Karpf AR Cancers (Basel). 2019 Feb 21;11(2). pii: cancers11020251. doi: 10.3390/cancers11020251. PubMed Journal

---

Articles Citing TLCV2-RB1

Articles
KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. D'Oto A, Fang J, Jin H, Xu B, Singh S, Mullasseril A, Jones V, Abu-Zaid A, von Buttlar X, Cooke B, Hu D, Shohet J, Murphy AJ, Davidoff AM, Yang J. Nat Commun. 2021 Dec 10;12(1):7204. doi: 10.1038/s41467-021-27502-2. PubMed
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Han W, Liu M, Han D, Toure AA, Li M, Besschetnova A, Wang Z, Patalano S, Macoska JA, Lam HM, Corey E, He HH, Gao S, Balk SP, Cai C. Mol Ther. 2022 Apr 6;30(4):1628-1644. doi: 10.1016/j.ymthe.2022.01.039. Epub 2022 Feb 2. PubMed

If you have published an article using this material, please email us at to have your article added to this page.